Evidence map›Paper›PMID 23821538›Full record

ArticleCancer2013

Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.

Ahmed O Kaseb, Junichi Shindoh, Yehuda Z Patt, Robert E Roses, Giuseppe Zimmitti, Richard D Lozano, Manal M Hassan, Hesham M Hassabo, Steven A Curley, Thomas A Aloia and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Controversies in the management of hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2019
    Review
  6. Review
  7. Review
  8. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.Journal of gastrointestinal oncology · 2017
    Review
  9. Review
  10. Review
  11. Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.Cancer control : journal of the Moffitt Cancer Center
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Ahmed O KasebDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Junichi Shindoh
Yehuda Z Patt
Robert E Roses
Giuseppe Zimmitti
Richard D Lozano
Manal M Hassan
Hesham M Hassabo
Steven A Curley
Thomas A Aloia
James L Abbruzzese
Jean-Nicolas Vauthey
The University of Texas MD Anderson Cancer Center · USUniversity of New Mexico · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Molecular Epidemiology of Chronic Liver DiseasesK07CA106458 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HASSAN, MANAL METWALLY · 2005 to 2009
$681k
Integrating plasma IGF-1 into novel classification of hepatocellular carcinomaR21CA170035 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KASEB, AHMED · 2012 to 2013
$366k
NCI NIH HHS CA016672NCI NIH HHS CA106458-01NCI NIH HHS CA170035-01NCI NIH HHS K07 CA106458NCI NIH HHS P30 CA016672NCI NIH HHS R21 CA170035
6 · The paper itself

Abstract

backgroundThe purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable hepatocellular carcinoma.

methodsThe study included 2 groups of patients treated with conventional high-dose PIAF (n = 84) between 1994 and 2003 and those without hepatitis or cirrhosis treated with modified PIAF (n = 33) between 2003 and 2012. Tolerance of chemotherapy, best radiographic response, rate of conversion to curative surgery, and overall survival were analyzed and compared between the 2 groups, and multivariate and logistic regression analyses were applied to identify predictors of response and survival.

resultsThe modified PIAF group had a higher median number of PIAF cycles (4 versus 2, P = .049), higher objective response rate (36% versus 15%, P = .013), higher rate of conversion to curative surgery (33% versus 10%, P = .004), and longer median overall survival (21.3 versus 10.6 months, P = .002). Multivariate analyses confirmed that positive hepatitis B serology (hazard ratio [HR] = 1.68; 95% confidence interval [CI] = 1.08-2.59) and Eastern Cooperative Oncology Group performance status ≥ 2 (HR = 1.75; 95% CI = 1.04-2.93) were associated with worse survival whereas curative surgical resection after PIAF treatment (HR = 0.15; 95% CI = 0.07-0.35) was associated with improved survival.

conclusionsIn patients with initially unresectable hepatocellular carcinoma, the modified PIAF regimen in patients with no hepatitis or cirrhosis is associated with improved response, resectability, and survival.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularCisplatinClinical Trials, Phase II as TopicCohort StudiesDoxorubicinFluorouracilHumansInterferon-alphaInterferon alpha-2Liver NeoplasmsMiddle AgedRecombinant ProteinsCisplatinDoxorubicinFluorouracilInterferon-alphaInterferon alpha-2Recombinant Proteinschemotherapydownsizinghepatocellular carcinomaliver resectionPIAFresponsesurvivaltolerance

Identifiers

PMID23821538
PMCPMC3775991
OpenAlexW1595010482

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.